By December, the US Food and Drug Administration (FDA) is expected to revoke approval of the drug Avastin for the treatment of advanced breast cancer. U.S. Senator David Vitter has described the anticipated move as “the beginning of a slippery slope leading to more and more rationing under the government takeover of health care,” says Sally C. Pipes, president and CEO of the Pacific Research Institute.
No cancer drug has ever been taken off the market based solely on “overall survivability.” Traditionally, calculations of a drug’s effectiveness have been based on tumour response and progression-free survival rates, says Pipes.
Here, Avastin is a miracle drug.
Government rationing doesn’t stop at Avastin.
It’s terrifying to think that distant, faceless bureaucrats are now making Americans’ health care decisions, says Pipes.
Source: Sally C. Pipes, The Era of Rationing Begins, Pacific Research Institute, September 27, 2010.
For text: http://www.pacificresearch.org/press/the-era-of-rationing-begins
For more on Health Issues: http://www.ncpa.org/sub/dpd/index.php?Article_Category=16
First published by the National Center for Policy Analysis, United States
FMF Policy Bulletin/ 05 October 2010




